Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)

Oncology
D HessSwiss Group for Clinical Cancer Research

Abstract

We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases. Patients > or =65 years who had received no prior chemotherapy for advanced breast cancer received up to six 21-day cycles of vinorelbine 20 mg/m(2) i.v. on days 1 + 8 with oral capecitabine on days 1-14 (1,000 vs. 1,250 mg/m(2) daily in patients with vs. without bone involvement). Median age was 72 years in patients with bone metastases (n = 47) and 75 years in patients without bone metastases (n = 23). Response rates were 43% (95% confidence interval, CI, 28.3-58.8) and 57% (95% CI = 34.5-76.8), respectively. Median time to progression was 4.3 (95% CI = 3.5-6.0 months) and 7.0 months (CI = 4.1-8.3), respectively. Neutropenia was the most common toxicity, with grade 3/4 occurring in 43 and 39%, respectively. Pulmonary embolism was seen in 5 and grade 3 thrombosis in 3 patients. Other toxicities were mild to moderate. These regimens of capecitabine and vinorelbine are active and well tolerated in patients with advanced breast cancer > or =65 years. Response rates were comparable to published results. The lower capecitabine doses appeared appropriat...Continue Reading

Citations

Nov 12, 2005·Cancer Chemotherapy and Pharmacology·Anne F SchottLaurence H Baker
Jul 18, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BeslijaUNKNOWN Central European Cooperative Oncology Group (CECOG)
May 20, 2011·Cancer Treatment Reviews·Marc DebledPierre Soubeyran
Nov 3, 2010·Critical Reviews in Oncology/hematology·Marc DebledLouis Mauriac
May 26, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Arlene Chan, Mark Verrill
Jan 31, 2013·Clinical Journal of Oncology Nursing·Diana Donovan
May 11, 2017·Breast Cancer Research and Treatment·B CabarrouThomas Filleron
May 16, 2019·Breast Cancer Research and Treatment·John SilberholzLinda Vahdat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.